

# Viswanath Devanarayan

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12093592/publications.pdf>

Version: 2024-02-01

34  
papers

4,830  
citations

279487

23  
h-index

377514

34  
g-index

40  
all docs

40  
docs citations

40  
times ranked

6662  
citing authors

#	ARTICLE	IF	CITATIONS
1	The MicroArray Quality Control (MAQC)-II study of common practices for the development and validation of microarray-based predictive models. <i>Nature Biotechnology</i> , 2010, 28, 827-838.	9.4	795
2	Fit-for-Purpose Method Development and Validation for Successful Biomarker Measurement. <i>Pharmaceutical Research</i> , 2006, 23, 312-328.	1.7	684
3	Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2004, 289, 1-16.	0.6	576
4	Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2008, 48, 1267-1281.	1.4	519
5	The concordance between RNA-seq and microarray data depends on chemical treatment and transcript abundance. <i>Nature Biotechnology</i> , 2014, 32, 926-932.	9.4	420
6	Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. <i>Journal of Immunological Methods</i> , 2008, 333, 1-9.	0.6	326
7	Comparison of RNA-seq and microarray-based models for clinical endpoint prediction. <i>Genome Biology</i> , 2015, 16, 133.	3.8	325
8	Confirmatory reanalysis of incurred bioanalytical samples. <i>AAPS Journal</i> , 2007, 9, E336-E343.	2.2	133
9	Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2011, 55, 878-888.	1.4	119
10	Development, validation, and implementation of a multiplex immunoassay for the simultaneous determination of five cytokines in human serum. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2005, 36, 1037-1044.	1.4	118
11	Recommendations for Use and Fit-for-Purpose Validation of Biomarker Multiplex Ligand Binding Assays in Drug Development. <i>AAPS Journal</i> , 2016, 18, 1-14.	2.2	71
12	Big data to smart data in Alzheimer's disease: The brain health modeling initiative to foster actionable knowledge. <i>Alzheimer's and Dementia</i> , 2016, 12, 1014-1021.	0.4	65
13	2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 3) Tj ETQq1,1,0.784314 rgBT 0,6 64	0.6	64
14	Recommendations for Systematic Statistical Computation of Immunogenicity Cut Points. <i>AAPS Journal</i> , 2017, 19, 1487-1498.	2.2	62
15	Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis. <i>Alzheimer Disease and Associated Disorders</i> , 2011, 25, 73-84.	0.6	57
16	Evaluation of Plasma Proteomic Data for Alzheimer Disease State Classification and for the Prediction of Progression From Mild Cognitive Impairment to Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2013, 27, 233-243.	0.6	53
17	Randomized Phase II Study of Carboplatin and Paclitaxel With Either Linifanib or Placebo for Advanced Nonsquamous Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 433-441.	0.8	45
18	Patient subgroup identification for clinical drug development. <i>Statistics in Medicine</i> , 2017, 36, 1414-1428.	0.8	42

#	ARTICLE	IF	CITATIONS
19	A PRIM approach to predictive signature development for patient stratification. <i>Statistics in Medicine</i> , 2015, 34, 317-342.	0.8	40
20	A multivariate predictive modeling approach reveals a novel CSF peptide signature for both Alzheimer's Disease state classification and for predicting future disease progression. <i>PLoS ONE</i> , 2017, 12, e0182098.	1.1	40
21	Recommendations for adaptation and validation of commercial kits for biomarker quantification in drug development. <i>Bioanalysis</i> , 2015, 7, 229-242.	0.6	39
22	Cerebrospinal Fluid Cytokine Dynamics Differ Between Alzheimer Disease Patients and Elderly Controls. <i>Alzheimer Disease and Associated Disorders</i> , 2012, 26, 322-328.	0.6	38
23	Screening for New Biomarkers for Subcortical Vascular Dementia and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2011, 1, 31-42.	0.6	35
24	Serum Phosphatidylethanolamine and Lysophosphatidylethanolamine Levels Differentiate Alzheimer's Disease from Controls and Predict Progression from Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2021, 80, 311-319.	1.2	27
25	VGF in Cerebrospinal Fluid Combined With Conventional Biomarkers Enhances Prediction of Conversion From MCI to AD. <i>Alzheimer Disease and Associated Disorders</i> , 2019, 33, 307-314.	0.6	24
26	Optimization of analytical and pre-analytical variables associated with an ex vivo cytokine secretion assay. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2006, 41, 189-195.	1.4	17
27	Recommendations for the Development and Validation of Immunogenicity Assays in Support of Biosimilar Programs. <i>AAPS Journal</i> , 2020, 22, 7.	2.2	17
28	Report on the AAPS Immunogenicity Guidance Forum. <i>AAPS Journal</i> , 2019, 21, 55.	2.2	14
29	Hearing Loss in Alzheimer's Disease Is Associated with Altered Serum Lipidomic Biomarker Profiles. <i>Cells</i> , 2020, 9, 2556.	1.8	14
30	Plasma biomarker signature associated with improved survival in advanced non-small cell lung cancer patients on linifanib. <i>Lung Cancer</i> , 2015, 90, 296-301.	0.9	12
31	Identification of a Simple and Novel Cut-Point Based Cerebrospinal Fluid and MRI Signature for Predicting Alzheimer's Disease Progression that Reinforces the 2018 NIA-AA Research Framework. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 537-550.	1.2	11
32	Comparison of Titer and Signal to Noise (S/N) for Determination of Anti-drug Antibody Magnitude Using Clinical Data from an Industry Consortium. <i>AAPS Journal</i> , 2022, 24, .	2.2	5
33	Are Lessons Learned in Setting Cut Points for Detection of Anti-Drug Antibodies Also Useful in Serology Assays for Robust Detection of SARS-CoV-2 Reactive Antibodies?. <i>AAPS Journal</i> , 2020, 22, 127.	2.2	3
34	Best practices for the development and fit-for-purpose validation of biomarker methods: a conference report. <i>AAPS Open</i> , 2022, 8, .	0.4	0